Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease

NCT00209014 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Celgene unable to continue funds.

Conditions

B-Cell Lymphoma
Hodgkin's Disease

Interventions

DRUG: Thalidomide

Sponsor

Emory University

Collaborators

[object Object]